WE DEVELOP PIONEER TARGETED THERAPIES FOR THE TREATMENT OF CANCER

Our research is based on the innovative concept of Dependence Receptors

Our biotechnology company developing therapies based on cellular mechanisms identified by a world-renowned research group

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer

Concept and link to cancer

Dependence Receptors are trans-membrane proteins that receive signals and transmit them inside cells. They play a key role in the control of tumor development and can be considered as tumor suppressors.

Dependence Receptors

Therapeutic strategy

Based on the concept of Dependance Receptors, the therapeutic strategy of NETRIS Pharma is to block the interaction between DRs and their ligands to restore the tumor suppressing functions.

therapeutic strategy

Research

NETRIS Pharma identifies the modifications of Dependance Receptors in cancer, perform proof of concept studies and develop monoclonal antibodies as drug candidates.

research

Located in Léon Bérard Cancer Center (Lyon, France),
NETRIS Pharma is a unique model of a biotechnology company
integrated within a comprehensive cancer center